BR112013033182A2 - compostos imidazopiridinil-aminopiridina substituída - Google Patents

compostos imidazopiridinil-aminopiridina substituída

Info

Publication number
BR112013033182A2
BR112013033182A2 BR112013033182A BR112013033182A BR112013033182A2 BR 112013033182 A2 BR112013033182 A2 BR 112013033182A2 BR 112013033182 A BR112013033182 A BR 112013033182A BR 112013033182 A BR112013033182 A BR 112013033182A BR 112013033182 A2 BR112013033182 A2 BR 112013033182A2
Authority
BR
Brazil
Prior art keywords
compounds
substituted imidazopyridinyl
aminopyridine compounds
aminopyridine
imidazopyridinyl
Prior art date
Application number
BR112013033182A
Other languages
English (en)
Inventor
Akihisa Matsuda
Anton Filikov
Chris Brassard
David Vensel
Jason Hill
Jean-Marc Lapierre
Kenichi Yoshida
Manish Tandon
Mark A Ashwell
Nivedita Namdev
Robert Nicewonger
Rocio Palma
Shin Iimura
Steffi Koerner
Takahiro Kitamura
Takanori Yamazaki
Takeshi Isoyama
Yanbin Liu
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of BR112013033182A2 publication Critical patent/BR112013033182A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

resumo “compostos imidazopiridinil-aminopiridina substituída” a presente invenção está relacionada a compostos imidazopiridinil-aminopiridina substituída e a métodos para sintetizar esses compostos. a presente invenção também está relacionada com composições farmacêuticas contendo compostos imidazopiridinil-aminopiridina substituída e a métodos de tratamento de distúrbios de proliferação celular; tais como o câncer, mediante administração destes compostos e composições farmacêuticas a indivíduos com necessidade desse tratamento.
BR112013033182A 2011-06-24 2012-06-21 compostos imidazopiridinil-aminopiridina substituída BR112013033182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500889P 2011-06-24 2011-06-24
PCT/US2012/043501 WO2012177844A2 (en) 2011-06-24 2012-06-21 Substituted imidazopyridinyl-aminopyridine compounds

Publications (1)

Publication Number Publication Date
BR112013033182A2 true BR112013033182A2 (pt) 2016-09-06

Family

ID=47362419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033182A BR112013033182A2 (pt) 2011-06-24 2012-06-21 compostos imidazopiridinil-aminopiridina substituída

Country Status (17)

Country Link
US (2) US8609688B2 (pt)
EP (1) EP2723741B8 (pt)
JP (1) JP6046710B2 (pt)
KR (2) KR101974673B1 (pt)
CN (1) CN103748093B (pt)
AU (2) AU2012272937B2 (pt)
BR (1) BR112013033182A2 (pt)
CA (1) CA2837727C (pt)
DK (1) DK2723741T3 (pt)
ES (1) ES2579855T3 (pt)
HK (1) HK1196371A1 (pt)
IL (3) IL229719A0 (pt)
MX (1) MX339862B (pt)
PH (1) PH12013502565B1 (pt)
TW (1) TWI561522B (pt)
WO (1) WO2012177844A2 (pt)
ZA (1) ZA201308929B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
US9770535B2 (en) * 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
JP5926180B2 (ja) 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
US9073903B2 (en) * 2010-02-17 2015-07-07 Jasco Pharmaceuticals, LLC Imidazole-2,4-dione inhibitors of casein kinase 1
EP2585053A4 (en) 2010-06-25 2014-02-26 Harvard College COMMON RELEASE OF STIMULATING AND HEMMING FACTORS FOR THE PRODUCTION OF TEMPORARY STABILIZED AND SPATULARLY LIMITED ZONES
PT2624873T (pt) 2010-10-06 2020-03-04 Harvard College Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
ES2878089T3 (es) 2011-04-28 2021-11-18 Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
JP6046710B2 (ja) * 2011-06-24 2016-12-21 アーキュール，インコーポレイティド 置換されたイミダゾピリジニル−アミノピリジン化合物
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
DK3122748T3 (en) 2014-03-24 2018-11-05 Arqule Inc METHOD OF PREPARING 3- (3- (4- (1-AMINOCYCLOBUTYL) PHENYL) -5-PHENYL-3H-IMIDAZO [4,5-B] PYRIDIN-2-YL) PYRIDIN-2-AMINE
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
MX2016013911A (es) * 2014-04-22 2017-03-07 Arqule Inc Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
AU2015311751B2 (en) 2014-09-05 2020-03-12 Arqule, Inc. Compositions and methods for treating proliferation disorders
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
CN105315161B (zh) * 2015-06-05 2017-08-04 厦门医学院 一类PKB/Akt抑制剂的关键中间体的制备方法
EP3411475A4 (en) 2016-02-06 2019-09-11 President and Fellows of Harvard College REGENERATION OF THE HEMATOPOIETIC NICHE TO RECONSTITUTE IMMUNITY
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
IL301567A (en) * 2020-09-30 2023-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A compound as an AKT KINASE inhibitor
EP4347041A1 (en) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
US20240079084A1 (en) * 2022-08-19 2024-03-07 Atomic Ai, Inc. Methods, systems, and media method applying machine learning to chemical mapping data for rna tertiary structure prediction

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3722992A1 (de) 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2002859C (en) 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO1996019991A1 (en) 1994-12-28 1996-07-04 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
AU3538899A (en) 1998-04-30 1999-11-23 Nippon Chemiphar Co. Ltd. Condensed imidazole derivative and therapeutic agent for liver disease
JP2000344780A (ja) 1998-09-24 2000-12-12 Fuji Photo Film Co Ltd 新規ベンゾピラン化合物、発光素子材料及びそれを使用した発光素子
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
CA2481940A1 (en) 2002-04-18 2003-10-30 Schering Corporation (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists
AR045134A1 (es) 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
DE602004020073D1 (de) * 2003-08-21 2009-04-30 Osi Pharm Inc 3-substituierte imidazopyridinderivate als c-kit-inhibitoren
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
WO2007056155A1 (en) 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
WO2007075555A2 (en) 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
CN101479255B (zh) 2006-03-22 2013-05-01 沃泰克斯药物股份有限公司 用于治疗增殖性病症的c-MET蛋白激酶抑制剂
CN100398540C (zh) 2006-04-03 2008-07-02 大连理工大学 芳杂环基咪唑并萘酰亚胺类化合物及其应用
CN101490037B (zh) 2006-07-11 2013-06-12 大熊制药株式会社 联芳基苯并咪唑衍生物以及包含该衍生物的药物组合物
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
MX2009009416A (es) 2007-03-02 2009-09-11 Schering Corp Derivados de bencimidazol y sus metodos de uso.
BRPI0813271A2 (pt) 2007-06-26 2014-12-30 Sanofi Aventis Síntese regiosseletiva catalisada por cobre de benzimidazóis e azabenzimidazóis
CN101802129B (zh) 2007-10-17 2014-01-01 第一毛织株式会社 有机光电装置用新化合物及包括该化合物的有机光电装置
KR20090007347U (ko) 2008-01-16 2009-07-21 춘-치 왕 가속 페달 포지션 센서를 구비한 자동차용 연료 공급 기구
RU2619463C2 (ru) * 2009-12-30 2017-05-16 Аркьюл, Инк. Замещенные имидазопиридинил-аминопиридиновые соединения, полезные при лечении рака
JP6046710B2 (ja) * 2011-06-24 2016-12-21 アーキュール，インコーポレイティド 置換されたイミダゾピリジニル−アミノピリジン化合物
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds

Also Published As

Publication number Publication date
EP2723741B1 (en) 2016-04-27
ES2579855T3 (es) 2016-08-17
AU2016269408A1 (en) 2016-12-22
WO2012177844A2 (en) 2012-12-27
JP6046710B2 (ja) 2016-12-21
MX2013015006A (es) 2014-12-08
US20140073635A1 (en) 2014-03-13
IL265897A (en) 2019-06-30
CA2837727C (en) 2019-12-03
PH12013502565A1 (en) 2017-05-29
PH12013502565B1 (en) 2017-05-29
TWI561522B (en) 2016-12-11
KR101974673B1 (ko) 2019-05-02
CN103748093A (zh) 2014-04-23
HK1196371A1 (zh) 2014-12-12
JP2014517072A (ja) 2014-07-17
CN103748093B (zh) 2016-06-01
EP2723741B8 (en) 2016-09-21
EP2723741A2 (en) 2014-04-30
US20120329791A1 (en) 2012-12-27
AU2016269408B2 (en) 2018-04-05
CA2837727A1 (en) 2012-12-27
IL286152A (en) 2021-10-31
ZA201308929B (en) 2016-03-30
KR20140040773A (ko) 2014-04-03
US8962619B2 (en) 2015-02-24
DK2723741T3 (en) 2016-06-06
KR20190015600A (ko) 2019-02-13
AU2012272937A1 (en) 2013-12-19
TW201311687A (zh) 2013-03-16
IL265897B (en) 2021-09-30
IL229719A0 (en) 2014-01-30
WO2012177844A3 (en) 2013-04-04
AU2012272937B2 (en) 2016-09-29
MX339862B (es) 2016-06-15
US8609688B2 (en) 2013-12-17
EP2723741A4 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
IN2012DN02081A (pt)
NZ700928A (en) Dna-pk inhibitors
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX343706B (es) Derivados heterocíclicos novedosos.
BR112014013526A2 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
BR112014019990A8 (pt) Compostos enediinos, seus conjugados e usos e métodos para esses compostos
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
WO2011082266A3 (en) Substituted heterocyclic compounds
MX2013000821A (es) Nuevas aminopirazoloquinazolinas.
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2013040227A3 (en) Therapeutic compounds
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
PH12016500092B1 (en) New azabenzimidazole derivatives
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]